• Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228).
  

PubMed=1568228
Metcalf R.A., Welsh J.A., Bennett W.P., Seddon M.B., Lehman T.A., Pelin-Enlund K., Linnainmaa K., Tammilehto L., Mattson K., Gerwin B.I., Harris C.C.
p53 and Kirsten-ras mutations in human mesothelioma cell lines.
Cancer Res. 52:2610-2615(1992)

PubMed=7972006; DOI=10.1073/pnas.91.23.11045; PMCID=PMC45163
Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H., Harris C.C.
Mutations and altered expression of p16INK4 in human cancer.
Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994)

CLPUB00243
Kahlos K.
The expression and possible role of manganese superoxide dismutase in malignant pleural mesothelioma.
Thesis PhD (1999); University of Oulu; Oulu; Finland

PubMed=11251971; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M
Kettunen E., Nissen A.-M., Ollikainen T., Taavitsainen M., Tapper J., Mattson K., Linnainmaa K., Knuutila S., El-Rifai W.
Gene expression profiling of malignant mesothelioma cell lines: cDNA array study.
Int. J. Cancer 91:492-496(2001)

PubMed=11283936; DOI=10.1002/1097-0142(20010401)91:7<1349::AID-CNCR1138>3.0.CO;2-D
Kahlos K., Soini Y., Sormunen R., Kaarteenaho-Wiik R., Paakko P., Linnainmaa K., Kinnula V.L.
Expression and prognostic significance of catalase in malignant mesothelioma.
Cancer 91:1349-1357(2001)